All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
PERTH, Australia – Australian immuno-oncology company Imugene Ltd. signed a deal to in-license an oncolytic virus known as CF33 from the City of Hope Comprehensive Cancer Center in Los Angeles, in a move to bolster its pipeline and open up a new area of growth for the company, said CEO Leslie Chong.